Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Willow Biosciences Inc T.WLLW

Alternate Symbol(s):  CANSF

Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial... see more

TSX:WLLW - Post Discussion

Willow Biosciences Inc > Willow, InMed and Baymedica
View:
Post by Bullknit101 on Jul 16, 2021 12:06am

Willow, InMed and Baymedica

Willow should join forces with InMed and Baymedica to counter Gingko InMed Announced LOI to Acquire BayMedica A leading rare cannabinoid manufacturer utilizing proprietary manufacturing techniques to produce rare, non-intoxicating, regulatory compliant, naturally-occurring cannabinoids Industry leading large-scale commercial production of CBC (cannabichromene) for B2B customers with current batch sizes in excess of 200kg; scalable to metric tonnes Revenue generating Strong revenue growth since first commercial sale in Q4 2019 Extensive, expanding patent portfolio in cannabinoid manufacturing and novel cannabinoid analogs Poised to launch several high-margin rare cannabinoids into the large and rapidly growing consumer health and wellness markets Has produced more than 20 natural cannabinoids using various manufacturing technologies including chemical synthesis and biosynthesis Extensive experience in drug discovery and pharmaceutical manufacturing
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities